Related Experiment Video
Updated: Jan 11, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
Bile Acid Binding Resins Improve Glucagon Receptor Agonist-Mediated Weight Loss in Diet-Induced Obese Mice
Teayoun Kim1, Mackenzie J Pearson2, Huixian Hong1
1Comprehensive Diabetes Center and Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Objective:
Glucagon-receptor (GCGR) agonism reguglates bile acid (BA) metabolism and promotes weight loss in diet-induced obese (DIO) mice. Thus, we hypothesized that BA signaling contributes to GCGR-stimulated weight loss.
Methods:
To test this hypothesis, we utilized BA-binding resins (BARs; colesevelam [Colsv] and cholestyramine [Cstyr]) to prevent intestinal BA reuptake. DIO C57Bl/6J mice were administered the GCGR agonist IUB288 or vehicle, in the presence or absence of BARs.
Results:
To our surprise, combined IUB288 and Colsv treatment reduced body weight and food intake compared to IUB288 or Colsv treatment groups in high fat diet (HFD)-fed mice. Moreover, acute IUB288 + Colsv treatment reduced fasting-stimulated HFD, but not chow, intake compared to IUB288 or Colsv treatments alone. We observed improved glucose homeostasis and reduced plasma cholesterol with combined IUB288 and Colsv, but not Colsv alone. Excitingly, liver steatosis was suppressed with IUB288 but not Colsv alone, and this benefit was further enhanced with combined treatment. Plasma BA profiles were regulated by both IUB288 and Colsv with concomitant modulation of liver and ileum BA regulatory mRNA expression. Similar findings were observed with the first-generation BAR Cstyr.
Conclusions:
Together, these studies suggest that BARs enhance the antiobesity effect of GCGR agonism in DIO mice, representing a novel antiobesity strategy.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: Glinides
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

